Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imaging amyloidosis with radiolabelled SAP.

Literature DB >> 7498219

Imaging amyloidosis with radiolabelled SAP.

P N Hawkins, M B Pepys.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 1995 PMID： 7498219 DOI： 10.1007/bf01254559

Source DB: PubMed Journal: Eur J Nucl Med ISSN： 0340-6997

× No keyword cloud information.

20 in total

1. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Authors: P N Hawkins; G A Tennent; P Woo; M B Pepys
Journal: Clin Exp Immunol Date: 1991-05 Impact factor: 4.330

Review 2. Treatment of amyloidosis.

Authors: S Y Tan; M B Pepys; P N Hawkins
Journal: Am J Kidney Dis Date: 1995-08 Impact factor: 8.860

3. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Authors: M B Pepys; T W Rademacher; S Amatayakul-Chantler; P Williams; G E Noble; W L Hutchinson; P N Hawkins; S R Nelson; J R Gallimore; J Herbert
Journal: Proc Natl Acad Sci U S A Date: 1994-06-07 Impact factor: 11.205

4. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression.

Authors: P N Hawkins; S Richardson; J E MacSweeney; A D King; D M Vigushin; J P Lavender; M B Pepys
Journal: Q J Med Date: 1993-06

5. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

Authors: D M Vigushin; M B Pepys; P N Hawkins
Journal: J Clin Invest Date: 1993-04 Impact factor: 14.808

6. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.

Authors: W L Hutchinson; G E Noble; P N Hawkins; M B Pepys
Journal: J Clin Invest Date: 1994-10 Impact factor: 14.808

7. Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains.

Authors: M L Baltz; K Gomer; A J Davies; D J Evans; G G Klaus; M B Pepys
Journal: Clin Exp Immunol Date: 1980-02 Impact factor: 4.330

8. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.

Authors: P N Hawkins; M J Myers; J P Lavender; M B Pepys
Journal: Lancet Date: 1988-06-25 Impact factor: 79.321

9. Structure of pentameric human serum amyloid P component.

Authors: J Emsley; H E White; B P O'Hara; G Oliva; N Srinivasan; I J Tickle; T L Blundell; M B Pepys; S P Wood
Journal: Nature Date: 1994-01-27 Impact factor: 49.962

10. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component.

Authors: P N Hawkins; M J Myers; A A Epenetos; D Caspi; M B Pepys
Journal: J Exp Med Date: 1988-03-01 Impact factor: 14.307

26 in total

Review 1. Amyloidosis.

Authors: M F Khan; R H Falk
Journal: Postgrad Med J Date: 2001-11 Impact factor: 2.401

2. SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

Authors: Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Arie Oosterhof; Toin H van Kuppevelt; Nicole C Smits; Stephen J Kennel
Journal: Nucl Med Biol Date: 2011-09-29 Impact factor: 2.408

Imaging amyloidosis with radiolabelled SAP.

1. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Review 2. Treatment of amyloidosis.

3. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

4. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression.

5. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

6. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.

7. Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains.

8. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.

9. Structure of pentameric human serum amyloid P component.

10. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component.

Review 1. Amyloidosis.

2. SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

3. A case of hepatomegaly.

4. Development and evaluation of agents for targeting visceral amyloid.

5. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.

6. Diagnosis and treatment of amyloidosis.

7. Long term results of heart transplantation in patients with amyloid heart disease.

8. A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5.

9. Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice.

10. Efflux transport of serum amyloid P component at the blood-brain barrier.